'Patients are Waiting'
This month, we spotlight the inspiring story of the Healthcare Businesswomen’s Association Woman of the Year, Yvonne Greenstreet.
Welcome to the May issue of Pharmaceutical Executive, where this year, we feature our annual profile and recognition of the Healthcare Businesswomen’s Association’s (HBA) newest Woman of the Year. For 2024, that esteemed honor went to Yvonne Greenstreet, CEO of Alnylam. In early January, the HBA announced the longtime executive, who, notably, has also served in leadership roles at Pfizer and GlaxoSmithKline, as WOTY, and this month honored Greenstreet and other HBA award winners at a celebratory event in New York City. “Throughout her 25 years in the biopharmaceutical industry, she has been instrumental in delivering medicines that transform the lives of people living with diseases in the United States, Europe, and around the world,” the HBA said of Greenstreet in its January release.
Today, as CEO of Alnylam, where she first joined in 2016 as chief operating officer, Greenstreet is an influential presence across all facets of the business, from strategy to value creation to organizational development and R&D. Alnylam’s treatment efforts are centered in RNAi therapeutics, with specific focus on addressing rare genetic diseases, cardio-metabolic conditions, and hepatic infectious diseases. As COO, Greenstreet led the launch of Alnylam’s first three commercial products, which officially ushered in RNAi drugs as a new class of medicine. In 2022, with Greenstreet now CEO, the company won FDA approval for Amvuttra, the first second-generation RNAi therapeutic, which treats the nerve damage caused by hereditary transthyretin amyloidosis, an aggressive, debilitating, and often fatal disease. “Without taking risks, you’re not going to be able to innovate,” Greenstreet tells editor Mike Hollan in our profile piece. “...This is a culture that we foster with a purpose, and we call ourselves fiercely innovative.”
For Greenstreet, the “fierce” part of that calling was perhaps fostered at an early age. She was born in London but raised in Ghana, where she witnessed, first-hand, significant community struggles in accessing quality healthcare. That experience formed a desire in Greenstreet to be a physician. And, today, it permeates in the culture at Alnylam, one built, she says, on the understanding that “patients are waiting.”
Please join me in congratulating Greenstreet on her HBA accolade, and we hope you enjoy reading about her inspiring journey and story.
Mike Hennessy Jr. is President and CEO of MJH Life Sciences
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Talphera Cuts NEPHRO CRRT Study Size, Secures $14.8 Million Private Placement
April 1st 2025The trial size adjustment, along with protocol modifications and the addition of higher-enrollment sites, is expected to facilitate completion of the NEPHRO CRRT study of Niyad in patients undergoing renal replacement therapy by the end of 2025.
